Studies related to Mucus Production and Serrapeptase

Evaluation Of Serratia Peptidase In Acute Or Chronic Inflammation Of Otorhinolaryngology Pathology: A Multicentre, Double-blind, Randomized Trial Versus Placebo

Effect Decrease
Trial Design Double blind
Trial Length 1-2 Weeks
Number of Subjects 193
Sex Both Genders
Age Range 18-29, 30-44, 45-64, 65+
Notes for this study:
In persons with acute or chronic ear, nose or throat disorders given 10mg of serrapeptase thrice daily (30mg total), supplementation was more effective than placebo in reducing abnormalities of mucus production and swallowing and was also analgesic.

Full details on all 4 studies are available to Examine Members. Try out the Examine Membership with a 14-day free trial.

Already a Member? Log in now to access.